INSIGHTFUL PERSPECTIVES FROM A TRUSTED AUTHORITY
Expert Opinion
PF carries a life-threatening prognosis1-4
When accurate diagnosis is delayed, progression may be more advanced or continue to advance, further complicating disease management.5,6
We have brought together perspectives from leading experts in the field of ILD who share their views on the current unmet needs in PF care.
Hear from Prof. Toby Maher on the definition of IPF and PPF
Prof. Toby Maher, Director of Interstitial Lung Disease, University of Southern California, USA
PC-XXX-101223 | Expiry Date: 4/14/2028
Hear from Prof. Marlies Wijsenbeek on what are some of the most common misconceptions heard about PPF and IPF
Prof. Marlies Wijsenbeen, Head of the Interstitial Lung Disease and Sarcoidosis, Erasmus MC, Netherlands
PC-XXX-101223 | Expiry Date: 4/14/2028
Hear from Prof. Michael Kreuter on the importance of patients understanding the progressive nature of IPF and PPF
Prof. Michael Kreuter, Director of Lung Centre Mainz, Germany
PC-XXX-101223 | Expiry Date: 4/14/2028
Hear from Prof. Anna-Maria Hoffmann-Vold on guideline recommendations for screening for ILD in CTD patients
Prof. Anna-Maria Hoffmann-Vold, Head of Strategic Area of Inflammatory and Fibrotic Disease, Oslo University Hospital, Norway
PC-XXX-101223 | Expiry Date: 4/14/2028
Hear from Prof. Steven Nathan on where are the current treatments for PPF and IPF fall short
Prof. Steven Nathan, Advanced Lung Disease and Lung Transplant Program at Inova Fairfox Hospital, USA
PC-XXX-101223 | Expiry Date: 4/14/2028
-
Distler JHW. et al. Nat Rev Rheumatol. 2019; 15(12): 705-730.
-
Lee H. et al. Sci Rep. 2024; 14(1): 8857.
-
Kolb M. et al. Respir Res. 2019; 20(1): 57.
-
Martines FJ. Nat Rev Dis Primers. 2017; 3: 17074.
-
kamoto M. et al. Respir Investig. 2016; 54(6): 445-453.
-
Selman M. et al. Ann Intern Med. 2001; 134(2): 136-151.
Document Number: PC-SA-102954
Expiry Date: